These innovative agents represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://bushragsqs855800.blogs-service.com/70113545/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide